The Clinical Impact of Anti-HLA Donor Specific Antibody Detection Through First Year Screening on Stable Kidney Transplant Recipients.

Anti-HLA Donor Specific Antibody (DSA) detection post kidney transplant has been associated with adverse outcomes, though the impact of early DSA screening on stable patients remain unclear. We analyzed impact of DSA detection through screening in 1st year stable patients ( = 736) on subsequent estimated glomerular filtration rate (eGFR), death censored graft survival (DCGS), and graft failure (graft loss including return to dialysis or re-transplant, patient death, or eGFR < 20 ml/min at last follow up). Patients were grouped using 1st year screening into DSA+ (Class I, II; = 131) or DSA- ( = 605). DSA+ group were more DR mismatched ( = 0.02), more sensitized (cPRA ≥90%, = 0.002), less Caucasian ( = 0.04), and had less pre-emptive ( = 0.04) and more deceased donor transplants ( = 0.03). DSA+ patients had similar eGFR (54.8 vs. 53.8 ml/min/1.73 m, = 0.56), DCGS (91% vs. 94%, = 0.30), and graft failure free survival (76% vs. 82%, = 0.11). DSA timing and type did not impact survival. Among those with a protocol biopsy ( = 515), DSA detected on 1st year screening was a predictor for graft failure on multivariate analysis (1.91, 95% CI 1.03-3.55, = 0.04). Overall, early DSA detection in stable patients was an independent risk factor for graft failure, though only among those who underwent a protocol biopsy.